From bench to bedside (B2B)
Malignant pleural effusion: from bench to bedside
... During the last decade, there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging and management. Expanding interest in this area has resulted in an increasing ...
10
From bench to bedside: use of human adipose-derived stem cells
... tool from the laboratory bench to bedside ...effect. Bedside use of ASC is advancing alongside basic ...site from the area of clinical need, strategies to improve the homing and ...
14
Evaluating genomic tests from bench to bedside: a practical framework
... research from bench to bedside do not describe in sufficient detail the evidence needed within each phase of its ...development. From experience, we have found that general models lack ...
9
MEK and the inhibitors: from bench to bedside
... Four distinct MAPK cascades have been identified and named according to their MAPK module. These are extra- cellular signal-regulated kinase (ERK1/2), c-Jun N-terminal kinase (JNK), p38 and ERK5. Each of these cascades ...
11
Linagliptin: from bench to bedside
... Summary: Clinical studies demonstrate an overall favorable safety profile, low risk for hypogly- cemia, weight neutrality, primarily nonrenal clearance, and efficacy for glycosylated hemoglobin reduction, typically ...
16
Cardiovascular disease in HIV patients: from bench to bedside and backwards
... switching from other PIs to the less atherogenic atazanavir could improve the endothelial function evaluated as fl ow- mediated dilation (FMD) of the brachial ...switching from triple combination treatment ...
9
Mesenchymal stromal cell therapy in COPD: from bench to bedside
... A Brazilian Phase I clinical trial employing autologous bone marrow mononuclear cells (BM-MCs) in COPD was carried out by the Genetic and Cell Therapy Laboratory of Universidade Estadual Paulista (São Paulo) in ...
11
Immune-mediated cerebellar ataxias: from bench to bedside
... obtained from these patients had no effect on cerebellar transmis- sion in slices [unpublished data] suggest that there are differences in epitope specificities between high-titer and low-titer anti-GAD65 ...
14
Cardiorespiratory control in the perioperative patient: from bench to bedside
... cause sudden changes in the end-tidal concentrations, so breaths which differed from the target value by more than 5% were ignored. A pulse oximeter using an ear probe (Ohmeda 3700 set to an averaging time of 2 s, ...
14
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
... microenvironment (PTME) [6]. Third, pancreatic cancer is associated with a massive infiltration of immunosup- pressive leukocytes into the tumor microenvironment [4, 5]. Fourth, the development of pancreatic cancer is ...
12
Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?
... regorafenib from the initial preclinical studies to the Phase III trials and critically examines the current clinical space occupied by regorafenib in the treatment of mCRC, at 5 years after its initial FDA ...
13
From bench to bedside, work in cell based myocardial regeneration therapy
... collected from the peripheral blood were transplanted into patients with intractable angina through transendocardial injection in a double- blind, randomized, placebo-controlled, and dose-escalating study, and ...
18
The Effects of Chronic Stress on Cd8 T Cells in Human Adults: An Examination From Bench to Bedside
... IL6, CXCL1, and CCL8) but did not find significant differences between the high and low groups. There was also no difference in ADRB2 expression between the high or low NE groups in lymphocytes, Tn, or Tm cells ...
135
Systemic treatment for lung carcinoids: from bench to bedside
... deriving from large, prospective, advanced-phase studies evaluating pulmonary carcinoids would suggest to choose primarily therapies supported by higher level of ...
19
Antimalarial compounds: from bench to bedside
... Current efforts focus, on the one hand, on research into novel compounds with mechanisms of action that are different to the traditionally used drugs, and, on the other hand, on measures to prevent or delay resistance ...
7
Heritable pulmonary hypertension: from bench to bedside
... children from two couples in which the males were carriers of a BMPR2 mutation followed in the French PAH referral centre have been born thanks to pre-implantation genetic ...
9
Heterogeneity of colon cancer: from bench to bedside
... Differences between RCC and LCRC also involve TLRs: specific TLRs are differently expressed in the intestinal epithelial cells among the proximal and the distal colon. Namely, data from animal models show that ...
8
B-Raf and the inhibitors: from bench to bedside
... cells from 5 patients showed that Raf inhibitor RLX4720 significantly lowered levels of phos- phorylated MEK and ERK, indicating that in hairy cell leukemia, mutated B-Raf was most likely the trigger for ...
9
B7x—from bench to bedside
... Currently, a phase Ia/Ib clinical trial (NCT03514121) with FPA150, a fully hB7x mAB with enhanced ADCC, in patients with advanced solid tumours is underway. The early results of this trial presented at the American ...
5
Variable ventilation from bench to bedside
... aspirates from oleic acid‐injured pigs, IL‐8 concentrations decreased after 5 h of variable controlled mechanical ventilation compared to conventional con- trolled mechanical ventilation but the investigated ...
10